As such, recipient gut integrity is maintained and can be partially attributed to intestinal crypt regeneration via IL-22 and GRP43, ultimately shifting the immune response toward reduced inflammation, resulting in GVHD protection. The gene discussed is IL22; the disease is graft versus host disease.